Alexandria Real Estate Equities, Inc

Alexandria Real Estate Equities, Inc(ARE)股票分析

$42.650

+2.120 (+4.97%)收盘时

Loading chart…
最高
43.005
开盘
40.950
成交量加权均价
42.14
成交量
3.13M
市值
20.35B
最低
40.772
成交额
131.95M
企业价值/息税折旧摊销前利润(TTM)
11.32

Alexandria Real Estate Equities, Inc. is a life science real estate investment trust. The Company is an owner, operator and developer of collaborative life science, agricultural technology (agtech), and advanced technology mega campuses in AAA innovation cluster locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. The Company, through its venture capital platform, provides strategic capital to life science, agrifoodtech, climate innovation, and technology companies. Its tenants include multinational pharmaceutical companies; public and private biotechnology companies; life science product, service and medical device companies; digital health, technology, and agtech companies; academic and medical research institutions; United States government research agencies; non-profit organizations, and venture capital firms. It has a Labspace asset base predominantly concentrated in markets with barriers to entry.

AI 分析 of Alexandria Real Estate Equities, Inc (ARE)

卖出

Given the current price of $41.62 and a low RSI of 19.49 indicating oversold conditions, the asset may seem attractive. However, the significant 1-year change of -45.76% and the downgrade from analysts, including BMO Capital reducing its target to $41, suggest ongoing challenges. The high insider selling activity and the need for significant asset sales to de-leverage raise concerns. Therefore, while there might be a potential for a rebound, the risks outweigh the potential rewards at this moment, making it a sell.

分析师评级(12)

上行空间 +33.29%
买入
7 买入
5 持有
0 卖出
当前: 42.65
最低
41.00
平均
56.85
最高
67.00

BMO Capital

2026-10-12

目标价

$41

Market Perform

JPMorgan

2026-09-24

目标价

$56

减持

Evercore ISI

2026-09-21

目标价

$59

跑赢大盘

Baird

2026-08-24

目标价

$52

中性

BofA

2026-08-24

目标价

$55

中性

估值指标

Alexandria Real Estate Equities, Inc(ARE)当前预期市盈率为 16.69,5 年平均预期市盈率为 47.03。

预期市盈率

合理
5 年均值 P/E
47.03
当前P/E
16.69
高估
82.72
低估
11.33

预期 EV/EBITDA

低估
5 年均值 EV/EBITDA
20.32
当前EV/EBITDA
11.32
高估
28.33
低估
12.31

预期市销率

低估
5 年均值 P/S
6.70
当前P/S
2.77
高估
9.54
低估
3.86

Alphio AI 对 ARE 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%ARE

$70.33

情景价格

基

基准

基准 · 50%ARE

$69.46

情景价格

悲

悲观

悲观 · 25%ARE

$59.44

情景价格

持有 ARE 的大户

Q

Quinn Opportunity Partners LLC

+ 持有ARE

-2.40%

3个月收益率

L

LaSalle Investment Management Securities, LLC

+ 持有ARE

-5.66%

3个月收益率

C

CenterSquare Investment Management LLC

+ 持有ARE

-8.04%

3个月收益率

C

Clal Financial Management Ltd

+ 持有ARE

-8.87%

3个月收益率

ARE 常见问题 —— 由 Alphio AI 解答

Alexandria Real Estate Equities, Inc. is a life science real estate investment trust. The Company is an owner, operator and developer of collaborative life science, agricultural technology (agtech), and advanced technology mega campuses in AAA innovation cluster locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. The Company, through its venture capital platform, provides strategic capital to life science, agrifoodtech, climate innovation, and technology companies. Its tenants include multinational pharmaceutical companies; public and private biotechnology companies; life science product, service and medical device companies; digital health, technology, and agtech companies; academic and medical research institutions; United States government research agencies; non-profit organizations, and venture capital firms. It has a Labspace asset base predominantly concentrated in markets with barriers to entry. It operates in the Real Estate sector (REAL ESTATE INVESTMENT TRUSTS industry).

Given the current price of $41.62 and a low RSI of 19.49 indicating oversold conditions, the asset may seem attractive. However, the significant 1-year change of -45.76% and the downgrade from analysts, including BMO Capital reducing its target to $41, suggest ongoing challenges. The high insider selling activity and the need for significant asset sales to de-leverage raise concerns. Therefore, while there might be a potential for a rebound, the risks outweigh the potential rewards at this moment, making it a sell.

12 analysts cover ARE: 7 rate it Buy, 5 Hold and 0 Sell. The average price target is 56.85.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易